ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China · Delayed Price · Currency is CNY 34.25
-1.10 (-3.11%)
At close: Sep 10, 2026
ChengDa Pharmaceuticals Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,188 | 6,165 | 3,057 | 3,934 | 4,912 | - | |
Market Cap Growth | 21.93% | 101.69% | -22.31% | -19.91% | - | - |
Enterprise Value | 4,257 | 5,243 | 1,875 | 2,523 | 3,463 | - |
Last Close Price | 34.25 | 40.48 | 19.90 | 24.80 | 30.74 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 43.24 | 46.13 | - |
PS Ratio | 10.82 | 15.17 | 9.18 | 9.50 | 11.94 | - |
PB Ratio | 2.47 | 2.94 | 1.43 | 1.73 | 2.22 | - |
P/TBV Ratio | 2.52 | 3.00 | 1.45 | 1.75 | 2.25 | - |
P/OCF Ratio | 96.32 | 181.22 | 106.70 | 20.48 | 103.06 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 8.88 | 12.90 | 5.63 | 6.09 | 8.42 | - |
EV/EBITDA Ratio | 73.22 | 98.23 | - | 25.67 | 32.80 | - |
EV/EBIT Ratio | - | - | - | 43.75 | 49.28 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.04 | - | - | 0.13 |
Debt / EBITDA Ratio | 0.89 | 1.11 | - | - | - | 0.48 |
Net Debt / Equity Ratio | -0.44 | -0.45 | -0.49 | -0.60 | -0.62 | 0.10 |
Net Debt / EBITDA Ratio | -16.06 | -17.55 | 48.35 | -13.88 | -13.08 | 0.36 |
Net Debt / FCF Ratio | -130.47 | 26.76 | 4.10 | 41.84 | 8.74 | -0.91 |
Asset Turnover | 0.20 | 0.17 | 0.14 | 0.17 | 0.27 | 0.68 |
Inventory Turnover | 2.15 | 1.90 | 1.56 | 1.67 | 1.75 | 2.66 |
Quick Ratio | 5.47 | 5.46 | 5.97 | 8.69 | 14.99 | 0.76 |
Current Ratio | 6.53 | 6.43 | 6.84 | 9.58 | 16.88 | 1.53 |
Return on Equity (ROE) | -1.06% | -0.56% | -1.25% | 4.05% | 7.75% | 20.28% |
Return on Assets (ROA) | -0.45% | -0.50% | -1.76% | 1.51% | 2.92% | 11.51% |
Return on Invested Capital (ROIC) | -1.44% | -1.70% | -6.88% | 5.76% | 8.80% | 19.45% |
Return on Capital Employed (ROCE) | -0.80% | -0.90% | -3.10% | 2.50% | 3.20% | 20.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.43% | -0.19% | -0.92% | 2.31% | 2.17% | - |
FCF Yield | 0.14% | -0.57% | -8.43% | -0.83% | -3.22% | - |
Dividend Yield | 0.55% | 0.49% | 1.00% | 0.81% | 0.61% | - |
Payout Ratio | - | - | - | 31.89% | 41.12% | 31.20% |
Buyback Yield / Dilution | -0.04% | 0.30% | 1.75% | -2.12% | -30.56% | 0.00% |
Total Shareholder Return | 0.51% | 0.80% | 2.76% | -1.31% | -29.95% | 0.00% |